Baldwin D R, Honeybourne D, Andrews J M, Ashby J P, Wise R
Department of Thoracic Medicine, Dudley Road Hospital, Birmingham, United Kingdom.
Antimicrob Agents Chemother. 1990 Jun;34(6):1017-9. doi: 10.1128/AAC.34.6.1017.
The bronchial mucosal concentrations of lomefloxacin were determined for specimens obtained by fiber-optic bronchoscopy and compared with simultaneous concentrations in serum. The 23 patients studied were given an oral dose of 400 mg once daily for 4 days to achieve steady-state levels. The median concentration in serum was 2.5 micrograms/ml (range, 1.0 to 5 micrograms/ml), and the median bronchial mucosal concentration was 5.0 micrograms/g (range, 0.7 to 18.6 micrograms/g). The median percent penetration was 177% (range, 69 to 541%). The concentrations in serum and mucosa exceeded the MIC for 90% of strains of organisms causing bronchial infections but not sufficiently to recommend lomefloxacin for the routine treatment of pneumococcal infections.
通过纤维支气管镜获取标本，测定了洛美沙星在支气管黏膜中的浓度，并与同时期血清中的浓度进行比较。对23例研究对象给予每日1次口服400mg、共4天的剂量，以达到稳态血药浓度。血清中的中位浓度为2.5μg/ml（范围1.0至5μg/ml），支气管黏膜中的中位浓度为5.0μg/g（范围0.7至18.6μg/g）。中位穿透率为177%（范围69至541%）。血清和黏膜中的浓度超过了引起支气管感染的90%菌株的最低抑菌浓度，但不足以推荐将洛美沙星用于肺炎球菌感染的常规治疗。
